A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination with Copanlisib in Patients with Metastatic Triple Negative Breast Cancer
A Phase I/II, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9?Engineered T Cells CTX112 in Subjects With Relapsed or Refractory B Cell Malignancies
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin a Conjugated Anti-CD22 Monoclonal Antibody to Frontline Therapy in Young Adults Ages 18-39 Years with Newly Diagnosed Precursor B-Cell ALL
Phase I/II Study of Cisplatin plus Romidepsin and Nivolumab in Metastatic Triple Negative Breast Cancer or BRCA Mutation-Associated Locally Recurrent or Metastatic Breast Cancer
EMBER-4: A Randomized, Open-Label, Phase III Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
A Phase Ib/II, Open-Label Study Of PF-07901801 In Combination with Glofitamab After a Fixed, Single Dose of Obinutuzumab in Participants with Relapsed/Refractory Diffuse Large B Cell Lymphoma Not Eligible for Stem Cell Transplantation